Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Erasca doubles down on RAS
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
